

Research Paper

Molecular mechanism of fluoroquinolones resistance in *Mycoplasma hominis* clinical isolates

Dong-Ya Meng¹, Chang-Jian Sun², Jing-Bo Yu¹, Jun Ma¹, Wen-Cheng Xue¹

¹Department of Clinical Laboratory, General Hospital of Shenyang Military Area Command, Shenyang, P.R. China.

²Department of Clinical Laboratory, No. 463 Hospital of Shenyang Military Area Command, Shenyang, P.R. China.

Submitted: May 7, 2012; Approved: September 9, 2013.

Abstract

To evaluate the molecular mechanism of fluoroquinolones resistance in *Mycoplasma hominis* (MH) clinical strains isolated from urogenital specimens. 15 MH clinical isolates with different phenotypes of resistance to fluoroquinolones antibiotics were screened for mutations in the quinolone resistance-determining regions (QRDRs) of DNA gyrase (*gyrA* and *gyrB*) and topoisomerase IV (*parC* and *parE*) in comparison with the reference strain PG21, which is susceptible to fluoroquinolones antibiotics. 15 MH isolates with three kinds of quinolone resistance phenotypes were obtained. Thirteen out of these quinolone-resistant isolates were found to carry nucleotide substitutions in either *gyrA* or *parC*. There were no alterations in *gyrB* and no mutations were found in the isolates with a phenotype of resistance to Ofloxacin (OFX), intermediate resistant to Levofloxacin (LVX) and Sparfloxacin (SFX), and those susceptible to all three tested antibiotics. The molecular mechanism of fluoroquinolone resistance in clinical isolates of MH was reported in this study. The single amino acid mutation in ParC of MH may relate to the resistance to OFX and LVX and the high-level resistance to fluoroquinolones for MH is likely associated with mutations in both DNA gyrase and the ParC subunit of topoisomerase IV.

Key words: *Mycoplasma hominis*, quinolones, drug resistance, mutation.

Introduction

Mycoplasma hominis (MH) is a Gram negative microorganism that lacks a typical bacterial cell wall. It is commonly found in the genitourinary tract of pregnant and non-pregnant women. The colonization rates for MH range between 20% and 30% worldwide (Sweih *et al.*, 2012; Garcia-de-la-Fuente *et al.*, 2008). MH can cause a wide range of diseases, such as genital infections in adults and may be involved in infections in premature and low birth-weight infants with clinical manifestations of septicaemia (Gonzalez-Jimenez *et al.*, 2006; Karabay *et al.*, 2006; Koshiba *et al.*, 2011). This tiny microorganism can also invade in central nervous system, joint, peritonitis, pyelonephritis and respiratory tract (Garcia *et al.*, 2007; Kacerovsky *et al.*, 2009; Koshiba *et al.*, 2011; Krijnen R. *et al.*, 2006; Myers *et al.*, 2010; Pascual 2010). Barykova (2011) reported that

MH infection may be involved in Prostate Cancer development.

MH was considered as a bacterium that is intrinsically resistant to quinolones like nalidixic acid but susceptible to fluoroquinolones, an important class of wide-spectrum antibacterial agents that target two enzymes essential for bacteria viability, the DNA gyrase and topoisomerase IV. However, the MH clinical strains isolated recently exhibited high-level resistance to various fluoroquinolones (Krausse *et al.*, 2010; Pereyre *et al.*, 2006; Kenny *et al.*, 2001). The molecular mechanism of fluoroquinolones resistance in clinical MH isolates remains to be elucidated. In present study, the quinolone resistance-determining regions (QRDRs) of DNA gyrase (*gyrA* and *gyrB*) and topoisomerase IV (*parC* and *parE*) in China clinical isolates were analyzed, and the molecular mechanism

of fluoroquinolone resistance in MH clinical isolates was reported.

Materials and Methods

Bacterial strains and antibiotics

Strains

15 MH clinical isolates identified by a kit produced by LIVZON Pharmaceutical Group Inc (China) with different phenotypes of resistance to quinolone antibiotics were obtained from urogenital specimens in Liaoning North Hospital, Shenyang City, China, from 2009 to 2010. MH reference strain ATCC 23114(PG21) was offered from Livzon Pharmaceutical Group INC and served as reference control.

Quinolone antibiotics

Ofloxacin (OFX), Levofloxacin (LVX) and Sparfloxacin (SFX) used in this study were provided by Livzon Pharmaceutical Group INC.

Determinations of minimal inhibitory concentrations

MH was cultured and its susceptibility to quinolone antibiotics was tested as described previously (Karabay *et al.*, 2006). The minimal inhibitory concentration (MIC) was determined as the lowest concentration of an antibiotic at which (i) the medium color did not change during the 24 h incubation at 37 °C and (ii) microscopic examination of the bottom of the plate well showed no growth of mycoplasma. The susceptibility breakpoints for MH to OFXLVX and SFX were with the MIC values of ≤ 1 (mg/L), and the resistant breakpoints for MH to OFXLVX and SFX were with MIC values of > 4 (mg/L). If the value of MIC was between the two breakpoints, then the MH strain was defined as intermediate (Meng *et al.*, 2009).

The amplification of QRDRs of MH by PCR

The primers were designed to amplify the QRDRs of *gyrA*, *gyrB*, *parC* and *parE* of MH as previously described (Béb  ar *et al.*, 1998). All primers were synthesized by

Shanghai Sangon Biological Engineering Technology & Services Co., Ltd. and the sequences were listed in Table 1.

The genomic DNA of MH strains were extracted with routine molecular biological procedures. Briefly, the precipitates from 1 mL of culture were harvested by centrifugation at 15,000 *g* for 30 min. The precipitates were treated with proteinase K at 55 °C for 2 h in digestion buffer, and the DNA was extracted using the phenol-chloroform method. The DNA extracts were stored at -70 °C for PCR amplification and sequencing. The PCR was performed with the parameters of 10 min at 92 °C, followed by 40 cycles of 1 min at 94 °C, 1 min at 57 °C, and 1 min at 72 °C, then with a final extension of 10 min at 72 °C. PCR products were analyzed by electrophoresis in 2% agarose gels.

Sequences analysis of QRDRs of MH

The PCR products were directly subjected to sequence analysis using a 384 Well Thermal Cycler. The nucleotide sequences of the PCR products were compared to those of the reference MH strain PG21 (GenBank accession no. NC_013511) by performing BLASTn at <http://www.ncbi.nlm.nih.gov/BLAST>.

Results

The MICs of three fluoroquinolones (SFX, OFX and LVX) against MH was determined by the Broth dilution method, and the results were presented in Table 2. The sequence of QRDRs of MH strain ATCC 23114 was found to be identical with the sequence of wild-type strain PG21 in GenBank. While for the clinical isolates, there were some mutations found in *gyrA*, *gyrB*, *parC* and *parE* (Table 2), which might related to the fluoroquinolones resistance.

Mutations in the genes of *gyrA* and *gyrB*

There were 7 SFX-resistant isolates that were found to carry nucleotide substitutions (Ser153-Leu) in *gyrA*, corresponding to the *E. coli* Ser83-Leu changes. Meanwhile, one of 7 SFX-resistant isolates was found to have another amino acid substitution, the Ser66-Ile. The other 8 clinical strains, including those resistant to OFX, LVX, or interme-

Table 1 - The designed primers for the amplification of MH QRDRs by PCR.

Name	Primer sequences	Amplicon size (gene)
MH3	forward 5'-TATGGTATGAGTGAACCTGG-3'	349-bp (<i>gyrA</i>)
MH4	reverse 5'-AATTAGGGAAACGTGATGGC-3'	
MH6	forward 5'-CTTCCTGGAAAATTAGCAGAC-3'	223-bp (<i>gyrB</i>)
MH7	reverse 5'-CTGTGCCTAAGGCGTGAATCA-3'	
MH11	forward 5'-CGTCGGATTTTATATTCAATG-3'	348 bp (<i>parC</i>)
MH13	reverse 5'-GGTGATTCCTTTAGCACCGTT-3'	
MH27	forward 5'-CTTTCAGGAAAATTAACCTCCT-3'	297 bp (<i>parE</i>)
MH28	reverse 5'-ATCAGTGTGATCAGCATCTGTCAT-3'	

Table 2 - Amino acid changes in GyrA, GyrB, ParC, and ParE in MH clinical isolates and reference strain.

MIC (µg/mL) of strain	Mutation position of*						
	OFX	LVX	SFX	GyrA	GyrB	ParC	ParE
1	64.00	64.00	16.00	Ser83- Leu	-	Lys134-Arg Ser80-Ile	-
2	32.00	16.00	8.00	Ser83-Leu	-	Lys134-Arg	-
3	32.00	16.00	8.00	Ser83-Leu	-	Lys134-Arg	-
4	64.00	32.00	16.00	Ser83-Leu Ser66-Ile	-	Lys134-Arg	-
5	16.00	16.00	8.00	Ser83-Leu	-	Lys134-Arg	-
6	16.00	16.00	8.00	Ser83-Leu	-	Lys134-Arg	-
7	16.00	16.00	8.00	Ser83-Leu	-	Lys134-Arg	-
8	32.00	16.00	4.00	-	-	Lys134-Arg	Asp426-Asn
9	8.00	4.00	2.00	-	-	Lys134-Arg	-
10	8.00	4.00	2.00	-	-	Lys134-Arg	-
11	16.00	16.00	0.50	-	-	Ser80-Ile	-
12	2.00	2.00	0.50	-	-	-	-
13	4.00	4.00	1.00	-	-	Lys134-Arg	Arg447-Lys
14	0.50	0.50	0.03	-	-	-	-
15	0.50	0.25	0.03	-	-	-	-
ATCC 23114 [#]	0.50	0.25	0.03	-	-	-	-

Note: SFX, sparfloxacin; LVX, levofloxacin; OFX, ofloxacin; *GyrA, GyrB, ParC, and ParE residue positions are based on the respective gene sequences for MH (4; this study). GyrA positions 136 and 153 corresponding to *E. coli* coordinates 66 and 83, respectively. ParC positions 91 and 145 corresponding to *E. coli* coordinates 80 and 134, respectively. ParE positions 432 and 453 corresponding to *E. coli* coordinates 426 and 447, respectively. [#] -, identical to that in the reference strain, PG21(GenBank accession no. NC_013511).

diate to OFX, LVX and SFX, or susceptible to all three tested antibiotics did not present any change in amino acid residue encoded by *gyrA*, while presented changes in amino acid residue encoded by ParC and ParE.

As for the *gyrB* genes of 15 clinical isolates, three nucleotide mutations (G2173A, G2278A, and A2197T) respectively were found. The most popular substitution was G2173A, which was happened in 7 clinical isolates. However, these nucleotide mutations did not cause amino acid change in translation.

Mutations in the genes *parC* and *parE*

Eleven out of 13 isolates with resistance or intermediate resistance to OFX, LVX were found to harbor a Lys134-Arg substitution in ParC. Among these 11 isolates, 7 strains simultaneously carried the Ser83-Leu substitution in GyrA protein. Only 2 out of the 13 clinical isolates presented two alterations in ParE, the Asp426-Asn and Arg447-Lys mutations. The two isolates also had the Lys134-Arg mutations in ParC.

Discussion

The present study reported that the 13 quinolone-resistant clinical isolates were found to carry target mutations in either *gyrA* and *parC* (7 isolates with resistance to OFX, LVX and SFX) or *parC* (4 isolates with no-resistance to SFX and resistance or intermediate resistance to OFX and LVX). There were no significant alterations in GyrB

amino acid, although several nucleotide substitutions can be detected in QRDR of *gyrB*. No mutations were found in clinical isolates with the phenotypes of resistant to OFX, intermediate resistant to LVX and SFX, and susceptible to all these three tested quinolone antibiotics. Several point mutations in the QRDR including the Ser83 Leu substitution in *gyrA* were required to observe significant reduced susceptibility to SFX, with values greater than 8 mg/L. In contrast, a single mutation in *parC* was enough to increase OFX and LVX MIC values up to 8 mg/L. This suggests that SFX interacts with the different QRDR targets (ParC and GyrA) whereas OFX primary target is *parC*. And this is consistent with previous findings (Bébéar *et al.*, 1999; Kenny *et al.*, 1999) who found mutations in *parC* and *gyrA* secondary to SFX exposure and mutations in *parC* only secondary to OFX exposure.

Our results also indicated that the Lys134-Arg substitution in ParC of MH might be related to its resistance to OFX and LVX. The Asp426-Asn (Mh8) and Arg447-Lys (Mh13) substitutions in ParE were detected, but the biological significance corresponding to these alterations remains elucidated.

The evolution of MH strains resistant to fluoroquinolones antibiotics was revealed in an in vitro studies reported previously (Bébéar *et al.*, 1997, 2000, 2003). The mechanism such a step by step resistant mutant in literature is unclear and need our further experiments to prove. The substitution of Ser83 in GyrA and Glu84 in ParC was con-

sidered to be associated with high-level resistance of MH against SFX. However, the Lys134-Arg substitution in ParC of MH in our results was firstly reported, which did not appeared in the induced experiment in vitro.

In conclusion, this study reports that the relation between fluoroquinolone resistance and mutation positions of QRDR of MH in clinical isolates. Our results indicate that the single amino acid mutation in ParC of MH may relate to the resistance to OFX and LVX and the high-level resistance to fluoroquinolones for MH is associated with mutations in both DNA gyrase and the ParC subunit of topoisomerase IV.

Acknowledgments

We thank Livzon Pharmaceutical Group INC for providing the ATCC 23114 (PG 21) strain and technical assistance.

References

- Barykova Y A, Logunov DY, Shmarov MM, Vinarov AZ, Fiev DN, Vinarova NA, Rakovskaya IV, Baker PS, Shyshynova I, Stephenson AJ, Klein EA, Naroditsky BS, Gintsburg AL, Gudkov AV (2011) Association of *Mycoplasma hominis* infection with prostate cancer. *Oncotarget* 2:289-297.
- Bébéar M, Renaudin J, Charron A (1999) Mutations in the *gyrA*, *parC*, and *parE* genes associated with fluoroquinolone resistance in clinical isolates of *Mycoplasma hominis*. *Antimicrob Agent Chemother* 43:954-956.
- Bébéar CM, Renaudin H, Charron A (1998) Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of *Mycoplasma hominis* obtained in vitro. *Antimicrob Agents Chemother* 42:2304-2311.
- Bébéar CM, Grau O, Charron A, Renaudin H, Gruson D, Bébéar C (2000) Cloning and nucleotide sequence of the DNA gyrase (*gyrA*) gene from *Mycoplasma hominis* and characterization of quinolone-resistant mutants selected in vitro with trovafloxacin. *Antimicrob Agent Chemother* 44:2719-2727.
- Bébéar, CM, Bove JM, Bebear C, Renaudin J (1997) Characterization of *Mycoplasma hominis* mutations involved in resistance to fluoroquinolones. *Antimicrob Agent Chemother* 41:269-273.
- Bébéar CM, Renaudin H, Charron A, Clerc M, Pereyre S, Bébéar C (2003) DNA Gyrase and Topoisomerase IV Mutations in Clinical Isolates of *Ureaplasma* spp. and *Mycoplasma hominis* Resistant to Fluoroquinolones. *Antimicrob Agent Chemother*. 47:3323-3325.
- Garcia C, Ugalde E, Monteagudo I, Saez A, Aguero J, Martinez-Martinez L (2007) Isolation of *Mycoplasma hominis* in critically ill patients with pulmonary infections: clinical and microbiological analysis in an intensive care unit. *Intensive Care Med* 33:143-147.
- Garcia-de-la-Fuente C, Minambres E, Ugalde E, Saez A, Martinez-Martinez L, Farinas MC (2008) Post-operative mediastinitis, pleuritis and pericarditis due to *Mycoplasma hominis* and *Ureaplasma urealyticum* with a fatal outcome. *J Med Microbiol* 57:656-657.
- Gonzalez-Jimenez MA, Villanueva-Diaz CA (2006) Epididymal stereocilia in semen of infertile men: evidence of chronic epididymitis. *Andrologi* 38:26-30.
- Kacerovsky M, Pavlovsky M, Tosner J (2009) Preterm premature rupture of the membranes and genital mycoplasmas. *Acta Medic* 52:117-120.
- Karabay O, Topcuoglu A, Kocoglu Gurel S, Gurel H, Ince NK (2006) Prevalence and antibiotic susceptibility of genital *Mycoplasma hominis* and *Ureaplasma urealyticum* in a university hospital in Turkey. *Clin Exp Obstet Gynecol* 33:36-38.
- Kenny GE, Young PA, Cartwright FD, Sjostrom KE, Huang WM (1999) SFX selects gyrase mutation in first-step *Mycoplasma hominis* mutants, whereas OFX selects topoisomerase mutation. *Antimicrob Agent Chemothe* 43:2493-2496.
- Kenny GE, Cartwright FD (2001) Susceptibilities of *Mycoplasma hominis*, *M. pneumoniae*, and *Ureaplasma urealyticum* to GAR-936, Dalbopristin, Dirithromycin, Evernimicin, Gatifloxacin, Linezolid, Moxifloxacin, Quinupristin-Dalbopristin, and Telithromycin compared to their susceptibility to reference Macrolides, Tetracyclines, and Quinolones. *Antimicrob Agent Chemother* 45:2604-2608.
- Koshiba H, Koshiba A, Daimon Y, Noguchi T, Iwasaku K, Kitawaki J (2011) Hematoma and abscess formation caused by *Mycoplasma hominis* following cesarean section. *Int J Womens Health* 17:15-18.
- Koshiba H, Koshiba A, Daimon Y, Noguchi T, Iwasaku K, Kitawaki J (2011) Hematoma and abscess formation caused by *Mycoplasma hominis* following cesarean section. *Int J Womens Health* 3:15-18.
- Krause R, Schubert S (2010) In-vitro activities of tetracyclines, macrolides, fluoroquinolones and clindamycin against *Mycoplasma hominis* and *Ureaplasma* ssp. isolated in Germany over 20 years. *Clin Microbiol Infect* 16:1649-1655.
- Krijnen M R, Hekker T, Algra J, Wuisman P I, Van Royen BJ (2006) *Mycoplasma hominis* deep wound infection after neuromuscular scoliosis surgery: the use of real-time polymerase chain reaction (PCR). *Eur Spine J* 17:599-603.
- Meng DY, Xue WC, Chen YN (2009) The epidemiology of mycoplasma infection and variance of resistance from 2003 to 2007 year. *Chin J of Lab Diag* 13:237-240.
- Myers PO, Khabiri E, Greub G, Kalangos A (2010) *Mycoplasma hominis* mediastinitis after acute aortic dissection repair. *Interact. Cardiovasc Thorac Surg* 11:857-858.
- Pascual A, Perez MH, Jatón K, Hafén G, Di Bernardo S, Cotting J, Greub G., Vaudoaux B (2010) *Mycoplasma hominis* necrotizing pleuropneumonia in a previously healthy adolescent. *BMC Infect Dis* 10:335.
- Pereyre S, Renaudin H, Charron A, Bebear C, Bebear CM (2006) Emergence of a 23S rRNA mutation in *Mycoplasma hominis* associated with a loss of the intrinsic resistance to erythromycin and azithromycin. *J Antimicrob Chemothe* 57:753-756.
- Sweih NA, Fadli AH, Omu AE, Rotimi VO (2012) Prevalence of *Chlamydia trachomatis*, *Mycoplasma hominis*, *Mycoplasma genitalium* and *Ureaplasma urealyticum* infections and seminal quality in infertile and fertile Men in Kuwait. *J Andro* 33:1323-1329.